Collaboration and innovation lead to refilled drug pipeline

07/11/2011 | Wall Street Journal, The

A slew of best-selling drugs will soon lose patent protection, but innovative drugs in the pipeline are likely to receive FDA approval and could soften pharma's fall off the so-called patent cliff. Bristol-Myers Squibb moved to encourage collaboration with outside researchers, resulting in the development of an innovative drug that uses the immune system to target melanoma, said Elliott Sigal, Bristol's head of research and development. "We're seeing a lot of innovation, much more than in recent memory," said Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT